Effect of number of cycles of S-1+docetaxel in adjuvant chemotherapy for Stage III gastric cancer

The intergroup phase III RINDBeRG Trial; Ramucirumab plus irinotecan beyond PD after ramucirumab for gastric cancer

An intergroup phase III RINDBeRG trial: ramucirumab plus irinotecan beyond PD after ramucirumab

高度リンパ節転移を伴う進行胃癌に対する周術期 Capecitabine＋Oxaliplatin療法の第II相試験（OGSG1701）

PhaseⅡstudy of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

Meta‑analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S‑1 plus cisplatin (SP) as first‑line treatment for advanced gastric cancer

Phase I dose‑escalation study on irinotecan, cisplatin, and S‑1 combination in chemotherapy‑naïve patients with HER2‑negative advanced gastric cancer (HERBIS‑4B, OGSG 1106)

Effect of the number of cycles of docetaxel + S‑1 therapy on long‑term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials

TRESBIEN (OGSG 2101) Encorafenib, binimetinib and cetuximab for early recurrent Stage II/III BRAF V600E-mutated CRC

Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease